ナトリウムグルコース共輸送体2（SGLT2）阻害剤の世界市場レポート 2025年

ナトリウムグルコース共輸送体2（SGLT2）阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.6％で154億米ドルに成長します。予測期間における成長の背景には、糖尿病有病率の上昇、肥満率の増加、糖尿病管理に対する意識の高まり、心臓病や腎臓病治療への応用拡大などがあります。予測期間における主な動向には、併用療法の統合、個別化医療アプローチ、技術改善、従来の医薬品開発などがあります。

糖尿病有病率の上昇は、ナトリウムグルコース共輸送体2（SGLT2）阻害薬市場の成長を牽引すると予想されます。糖尿病は、インスリン分泌、インスリン作用、またはその両方の障害による高血糖を特徴とする代謝疾患群を指します。糖尿病患者の増加は、都市化、ストレス、環境汚染、ヘルスケアサービスへのアクセス制限などの要因に起因しています。SGLT2阻害薬は、腎臓におけるグルコースの再吸収を阻害することにより血糖値を下げ、尿中への排泄を促す糖尿病治療に用いられます。これらの阻害剤は、心血管や腎臓にも効果をもたらすため、糖尿病とその合併症を管理するための重要な治療選択肢となっています。例えば、2023年12月、政府機関であるオーストラリア統計局は、2022年にオーストラリア人の5.3％、約130万人が糖尿病と診断されたと報告しました。この割合は男性（5.8％）と女性（4.9％）で同程度でした。糖尿病の有病率は着実に上昇しており、特に高齢者層では75歳以上の18.7％が罹患しています。2型糖尿病が87.6％を占めています。海外で生まれたこと、恵まれない地域に住んでいること、障害を持っていることなどの要因が、糖尿病罹患率の上昇につながっています。その結果、糖尿病有病率の増加がSGLT2阻害薬市場の成長を促進しています。

SGLT2阻害薬市場の主要企業は、患者の転帰と血糖管理を強化するため、二重阻害薬療法の開発に注力しています。二重阻害薬治療は、ナトリウム-グルコース共輸送体1および2（SGLT1およびSGLT2）の両方を標的とし、心不全や糖尿病などの症状に対する治療効果を改善します。例えば、2023年5月、米国のバイオ医薬品会社Lexicon Pharmaceuticals Inc.は、新規のSGLT1とSGLT2のデュアル阻害剤であるソタグリフロジンのFDA承認を取得しました。本剤は、1日1回服用で、心不全、2型糖尿病、慢性腎臓病およびその他の心血管危険因子を有する成人における心血管死、心不全による入院および心不全による緊急受診を減少させる。ソタグリフロジンは、腎臓でのグルコースおよびナトリウムの再吸収を抑制することにより、前負荷および後負荷を減少させ、交感神経の活動を低下させます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ナトリウムグルコース共輸送体2（SGLT2）阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：成長率分析
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場の実績：規模と成長, 2019-2024
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界ナトリウムグルコース共輸送体2（SGLT2）阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インヴォカナ
• ジャディアンス
• フォシーガまたはフォシーガ
• スグラット
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口経路
• その他の投与経路
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 在宅ケア設定
• クリニック
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場インヴォカナのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックインボカナ（カナグリフロジン）
• ブランドインヴォカナ
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場、Jardianceのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックジャディアンス（エンパグリフロジン）
• ブランド化されたジャディアンス
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場、フォシーガまたはフォシーガの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックフォシーガ（ダパグリフロジン）
• ブランド名：フォシーガ
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場、Suglatのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 糖尿病治療薬「スーグラ（ソタグリフロジン）」
• 心不全のためのスーグラ（ソタグリフロジン）

第7章 地域別・国別分析

• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：競合情勢
• ナトリウムグルコース共輸送体2（SGLT2）阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmBH
• Astellas Pharma Inc
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Ltd
• Sumitomo Dainippon Pharma Co. Ltd.
• Taisho Pharmaceutical Holdings Co. Ltd.
• Lupin Limited
• Glenmark pharmaceuticals
• Torrent Pharmaceuticals Ltd
• Mankind Pharma Ltd
• Kissei Pharmaceutical Co. Ltd.
• Patsnap Synapse

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ナトリウムグルコース共輸送体2（SGLT2）阻害剤市場2029：新たな機会を提供する国
• ナトリウムグルコース共輸送体2（SGLT2）阻害剤市場2029：新たな機会を提供するセグメント
• ナトリウムグルコース共輸送体2（SGLT2）阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs designed to manage type 2 diabetes by blocking the SGLT2 protein in the kidneys. This action prevents the reabsorption of glucose, leading to its excretion in the urine and helping to lower blood glucose levels. In addition to their role in controlling blood sugar, SGLT2 inhibitors can aid in weight loss and lower blood pressure, and they offer additional cardiovascular and renal benefits, which are valuable for managing diabetic complications.

The main types of SGLT2 inhibitors include Invokana, Jardiance, Farxiga (or Forxiga), and Suglat. Invokana is a prescription medication used to reduce blood sugar levels in adults with type 2 diabetes. These medications are generally administered orally and are utilized by various end users such as hospitals, homecare settings, and clinics.

The sodium glucose cotransporter 2 (SGLT 2) inhibitors market research report is one of a series of new reports from The Business Research Company that provides sodium glucose cotransporter 2 (SGLT 2) inhibitors market statistics, including the sodium glucose cotransporter 2 (SGLT 2) inhibitors industry's global market size, regional shares, competitors with a sodium glucose cotransporter 2 (SGLT 2) inhibitors market share, detailed sodium glucose cotransporter 2 (SGLT 2) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the sodium glucose cotransporter 2 (SGLT 2) inhibitors industry. This sodium glucose cotransporter 2 (SGLT 2) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market size has grown strongly in recent years. It will grow from $10.17 billion in 2024 to $11.07 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to early clinical trial successes, rising regulatory approvals, increasing diabetes diagnosis rates, and the demand for innovative diabetes treatments.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $15.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.

The rising prevalence of diabetes is expected to drive the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes refers to a group of metabolic conditions marked by high blood sugar levels due to defects in insulin secretion, insulin action, or both. The increase in diabetes cases can be attributed to factors such as urbanization, stress, environmental pollution, and limited access to healthcare services. SGLT2 inhibitors are used in diabetes treatment to lower blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its excretion in urine. These inhibitors also provide cardiovascular and renal benefits, making them a key treatment option for managing diabetes and its complications. For example, in December 2023, the Australian Bureau of Statistics, a government agency, reported that in 2022, 5.3% of Australians, or around 1.3 million people, were diagnosed with diabetes. The rates were similar between males (5.8%) and females (4.9%). Diabetes prevalence has been rising steadily, particularly among older populations, with 18.7% of people aged 75 and older affected. Type 2 diabetes accounts for 87.6% of cases. Factors such as being born overseas, living in disadvantaged areas, and having a disability are linked to higher diabetes rates. Consequently, the increasing prevalence of diabetes is propelling the growth of the SGLT2 inhibitor market.

Leading companies in the SGLT2 inhibitor market are focusing on developing dual inhibitor therapies to enhance patient outcomes and blood sugar management. Dual inhibitor therapies target both sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) to improve treatment efficacy for conditions such as heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., a U.S.-based biopharmaceutical firm, received FDA approval for sotagliflozin, a novel dual SGLT1 and SGLT2 inhibitor. This once-daily tablet is designed to reduce cardiovascular death, hospitalizations for heart failure, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Sotagliflozin helps by reducing renal glucose and sodium reabsorption, leading to decreased preload and afterload, as well as reduced sympathetic activity.

In December 2022, Torrent Pharmaceuticals, an India-based pharmaceutical company, formed a partnership with Boehringer Ingelheim International GmbH to co-market diabetes and cardiovascular disease treatments. This collaboration aims to develop solutions for glycemic control in adults with type 2 diabetes mellitus. Empagliflozin, a product of this partnership, not only reduces the risk of cardiovascular death in individuals with type 2 diabetes and cardiovascular disease but also lowers the risk of cardiovascular death and hospitalizations for heart failure in adults with heart failure. Boehringer Ingelheim International GmbH, a Germany-based pharmaceutical company, specializes in developing and manufacturing health products for humans and animals.

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki pharmaceutical Co Ltd.

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market consists of sales of luseogliflozin, remogliflozin, tofogliflozin and sergliflozin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sodium glucose cotransporter 2 (sglt2) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sodium glucose cotransporter 2 (sglt2) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sodium glucose cotransporter 2 (sglt2) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat
• 2) By Route Of Administration: Oral Route; Other Route Of Administration
• 3) By End User: Hospitals; Homecare Settings; Clinics
• Subsegments:
• 1) By Invokana: Generic Invokana (Canagliflozin); Branded Invokana
• 2) By Jardiance: Generic Jardiance (Empagliflozin); Branded Jardiance
• 3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin); Branded Farxiga
• 4) By Suglat: Suglat (Sotagliflozin) For Diabetes; Suglat (Sotagliflozin) For Heart Failure
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Characteristics

3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trends And Strategies

4. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Growth Rate Analysis
• 5.4. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Total Addressable Market (TAM)

6. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segmentation

• 6.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Invokana
• Jardiance
• Farxiga Or Forxiga
• Suglat
• 6.2. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Route
• Other Route Of Administrations
• 6.3. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare Settings
• Clinics
• 6.4. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Invokana, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Invokana (Canagliflozin)
• Branded Invokana
• 6.5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Jardiance, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Jardiance (Empagliflozin)
• Branded Jardiance
• 6.6. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Farxiga Or Forxiga, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Farxiga (Dapagliflozin)
• Branded Farxiga
• 6.7. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Suglat, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Suglat (Sotagliflozin) For Diabetes
• Suglat (Sotagliflozin) For Heart Failure

7. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Regional And Country Analysis

• 7.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 8.1. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 9.1. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 9.2. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 10.1. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 11.1. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 11.2. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 12.1. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 13.1. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 14.1. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 14.2. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 15.1. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 15.2. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 16.1. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 17.1. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 18.1. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 19.1. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 20.1. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 21.1. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 21.2. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 22.1. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 23.1. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 23.2. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 24.1. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 24.2. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 25.1. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 25.2. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 26.1. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 26.2. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 27.1. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 28.1. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 28.2. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

• 29.1. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
• 29.2. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Landscape
• 30.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Eli Lilly and Company
• 31.4. Boehringer Ingelheim International GmBH
• 31.5. Astellas Pharma Inc
• 31.6. Daiichi Sankyo Company Limited
• 31.7. Sun Pharmaceutical Industries Ltd
• 31.8. Sumitomo Dainippon Pharma Co. Ltd.
• 31.9. Taisho Pharmaceutical Holdings Co. Ltd.
• 31.10. Lupin Limited
• 31.11. Glenmark pharmaceuticals
• 31.12. Torrent Pharmaceuticals Ltd
• 31.13. Mankind Pharma Ltd
• 31.14. Kissei Pharmaceutical Co. Ltd.
• 31.15. Patsnap Synapse

32. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

34. Recent Developments In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

35. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer